ArticleBiotechnology and bioengineering2026
New Hyaluronic Acid-Based Bioengineered 3D Scaffold: Fabrication and Potential for Oocyte In Vitro Maturation.
Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Oocyte in vitro maturation (IVM) is a valuable tool in human and animal reproduction, but its efficiency remains lower than that obtainable in vivo, partly due to suboptimal used culture conditions. This study aimed to evaluate the effects of adding hyaluronic acid (HA) to spherical alginate-based 3D scaffolds to better mimic the native ovarian intrafollicular microenvironment. HA (2 or 4 mg/mL) was incorporated into an alginate/collagen I/granulosa cell matrix to fabricate bioengineered microbeads, which were characterized for morphology, microstructure and mechanical properties. Sheep cumulus-oocyte complexes were encapsulated and cultured for 24 h in such microbeads for IVM and subsequent IVEC. HA-enriched scaffolds displayed sphericity, stability, concentration-dependent reduction in pore size and slight increase in stiffness. In scaffolds with 2 mg/mL HA, cumulus cell expansion, metaphase II and embryo cleavage rates were significantly improved compared to controls, scaffolds without HA and 4 mg/mL HA. Apoptosis levels in cumulus and granulosa cells were significantly lower with 2 mg/mL HA. SEM imaging suggested cell-driven extracellular matrix (ECM) remodelling during IVM. These results indicate that 2 mg/mL HA provides the optimal balance between structural support and mechanical compliance, promoting oocyte maturation. Further studies are needed to elucidate the underlying molecular mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.